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PEGylated and non-PEGylated ORMOSIL nanoparticles 
prepared by microemulsion condensation of vinyltriethoxy-10 
silane (VTES) were investigated in detail for their micro-
structure and ability to deliver photoactive agents. With 
respect to pure silica nanoparticles, organic modification 
substantially changes the microstructure and the surface 
properties. This in turn leads to a modulation of both the 15 
photophysical properties of embedded photosensitizers and 
the interaction of the nanoparticles with biological entities as 
serum proteins. The flexibility of the synthetic procedure 
allows the rapid preparation and screening of multifunctional 
nanosystems for photodynamic (PDT) therapy. Selective 20 
targeting of model cancer cells was tested by using folate, 
integrin specific RGD peptide and anti-EGFR antibodies. 
Data suggest the interference of the stealth-conferring layer 
(PEG) with small targeting agents, but not with bulky 
antibodies. Moreover, we showed that selective photokilling 25 
of tumour cells may be limited even in the case of efficient 
targeting because of intrinsic transport limitations of active 
cellular uptake mechanisms or suboptimum localization.  
Introduction 
Over the last few years, silica nanoparticles have attracted a great 30 
deal of interest as materials for biomedical applications.1 At first 
glance, this may appear quite surprising. Unlike other 
nanomaterials, silica nanoparticles do not have any nanosize-
related properties, nor are they easily biodegraded.2 So, what 
makes silica nanoparticles so attractive? The answer lies in their 35 
highly cross-linked polymeric nature. Being of polymeric 
structure they can accommodate in their interior (either in the 
silica matrix or within pores) active molecules, such as drugs, 
dyes and photosensitizers.3 The loading capacity of silica 
nanoparticles is hence much higher than that achievable with 40 
other nanomaterials which  allow only surface grafting, and this 
enables their use for drug delivery applications. On the other 
hand, their highly cross-linked nature renders silica nanoparticles 
much more rigid than other polymeric nanoparticles. This makes 
it possible to process them into very complex structures, 45 
including mesoporous particles,1c,4 nanoshells5 and multi-shell 
particles.3,6 Such versatility has opened the way to the realization 
of several sophisticated systems, such as gated porous particles 
for controlled release,1a,f multimodal imaging and delivery 
agents,1 chemical sensors.7 Notably, silica does not need to be 50 
made only by silicon oxide. Using organosilane precursors in the 
formation of the silica network, organically modified silica 
(ORMOSIL) materials can be obtained.8 Here, the possibilities 
for tuning the nanoparticles properties, either of the surface and
 55 
Scheme 1. One-pot synthesis of doped, PEGylated and functional ORMOSIL nanoparticles. Any of the components indicated in the caption, with the 
exception of the surfactant may be omitted to prepare nanoparticles with different features. 
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of the bulk phase, or by changing the nature of the organic moiety 
introduced, are very broad. A class of ORMOSIL nanoparticles 
that has recently emerged as an attractive candidate for 
nanomedicine applications comprises those prepared by the base-
catalyzed condensation of vinyl-triethoxysilane (VTES, chart 1) 5 
in aqueous surfactant solutions.  
This synthetic protocol was first proposed by P. N. Prasad and 
co-workers in 2003 for the development of photosensitizer 
delivery agents in photodynamic therapy (PDT).9 This approach 
enabled a series of very elegant advances stemming from the 10 
original photosensitizer loaded particles,10 including two-photon 
excitation of the photosensitizer through Förster energy transfer 
from a co-included antenna11 and matrix enhancement of the 
singlet oxygen production quantum yield.12 Applications for 
fluorescent probes,13 encapsulation of other nanoparticles,14 DNA 15 
transfection15 and targeted delivery16 were also reported. 
Advantages of such ORMOSIL nanoparticles are many. Firstly, 
the use of the organosilane precursor provides a low polarity 
interior that favours the inclusion of hydrophobic molecules but 
does not prevent their release in biological fluids.17 Secondly, the 20 
properties of both the bulk material and probably also of the 
particles surface may be tailored, as mentioned earlier, by the use 
of different organosilane precursors. But the most relevant feature 
is brought about by the microemulsion polymerization protocol 
used for their preparation. In fact, not only does the surfactant 25 
aggregate act as a nanocontainer where the organosilane 
polymerization is confined, but it can also play the role of a 
template, where it pre-organizes the nanoparticle components 
placing them precisely in the site they are needed to perform their 
function. Hence, as demonstrated by Prasad and also by us, dye-30 
doped surface functionalized nanoparticles can be prepared by a 
one pot-procedure.16,18 Indeed, we recently showed, by taking full 
advantage of such an approach, that densely PEGylated 
nanoparticles can be prepared18 and that such a dense coating 
reduces the toxic19 and pro-coagulant20 properties of particles 35 
themselves and avoids capture by immune system cells.18 While 
these findings further amplify the interest in nanomedicine 
applications of ORMOSIL nanoparticles, their structure and 
characteristics have yet to be fully investigated. By a detailed 
investigation of the chemical, structural and biological properties 40 
of PEGylated and non-PEGylated ORMOSIL nanoparticles made 
with VTES, we have acquired herein a deeper comprehension of 
their properties and potential for applications. 
Results and Discussion 
Chemical microstructure and surface properties 45 
The synthesis of the VTES-ORMOSIL nanoparticles (Scheme 1) 
may be regarded as a variation of the well-known Stober 
procedure,21 involving the ammonia-catalysed polymerization of 
alkoxysilane precursors in ethanol. The main difference here is 
that the reactions occur in water and in the presence of a 50 
surfactant (AOT, Tween, Brij) that controls the growth of the  
 
Figure 1. ATR-IR Spectra of lyophilized ORMOSIL nanoparticles (blue) 
and PEGylated ORMOSIL nanoparticles (green).  
nanoparticles. Such modifications and the use of an organosilane 55 
precursor may influence the nanoparticles microscopic structure. 
With this view, we prepared VTES nanoparticles with a diameter 
of 50 nm using the Brij surfactant for spectroscopic 
characterization. The ATR-IR spectrum (Figure 1, blue) contains 
all the main features of VTES-containing materials.22 The most 60 
intensive band, at about 1100 cm-1 is due to the asymmetric 
stretching of the Si–O–Si bridges, and, as usually found for 
ORMOSIL materials, splits into two separate bands at 1040 (TO 
mode) and 1110 (LO mode) cm-1. Interestingly, the position of 
these signals is 20-40 nm red-shifted with respect to the usual 65 
values found in VTES containing sol-gel films prepared by acid 
catalysis,22 possibly indicating a highly porous structure of the 
nanoparticles. The symmetric stretching of the same silicon–
oxygen bridges is responsible of the band at about 760 cm-1. The 
sharp signals at 1409 (in plane CH2 bending) and 1602 (C=C 70 
stretching) cm-1 arise from the vibrations of the vinyl groups. On 
the other hand, the sharp signal at 966 cm-1, is likely the result of 
the overlap of the signals arising from Si-OH stretching and vinyl 
CH2 wagging.  
More detailed structural information is obtained by MAS solid 75 
state NMR. 13C NMR (Figure 2a, blue) confirmed the complete 
hydrolysis of the alkoxysilane precursor since no signals related 
to the ethoxy moieties are visible in the spectrum. The two-broad 
signals at 145 and 135 ppm arise from the two carbon atoms of 
the vinyl residues. On the other hand, a series of sharp signals is 80 
visible between 80 and 20 ppm, which corresponds very well to 
the Brij surfactant. We were not able to remove the surfactant 
signals either by extensive ultrafiltration or Soxlet extraction with 
boiling ethanol, indicating that it is likely physically entrapped in 
the ORMOSIL matrix. The 29Si spectrum (Figure 2b, blue) shows 85 
two signals at -77 and -68 ppm, arising respectively from fully 
condensed T3 and partially condensed T2 silicon atoms.  
Integration of the signals indicates that T2 atoms are only 10% of  
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Figure 2. 29Si MAS (a) and 13C MAS (b) solid state NMR of lyophilized 
ORMOSIL nanoparticles (blue) and PEGylated ORMOSIL nanoparticles 
(green). C=C indicates the vinylic carbons and C-O the carbons bound to 
oxygen of the PEG polymer.  The symmetric signals (*) at 70 and 170 5 
ppm in the 29Si spectrum are spinning bands. 
the total, indicating a highly condensed structure. When 
compared with pure silica nanoparticles, the VTES ORMOSIL 
particles reveal interesting differences. Early studies by van 
Blaaderen indicated that silica nanoparticles prepared either via 10 
the Stöber protocol (TEOS condensation in ethanol) or via the 
micro-emulsion protocol (TEOS condensation in water/ 
cyclohexane microemulsion) are characterized by incomplete 
hydrolysis of the precursor alkoxysilanes and much less 
condensed structure (67 and 55% of fully condensed Q4 silicon 15 
atoms, respectively).23 Only the commercial Ludox particles, that 
are prepared by condensation of silicates in water, present a 
similarly highly condensed structure, with 85% of Q4 silicon 
atoms.23 
The degree of hydrolysis and condensation, however, does not 20 
influence surface charge, which is one of the most important 
features of nanoparticles for biomedical applications since it 
determines their stability in high ionic strength biological fluids 
and ability to interact with cells. Z-potential measurements 
performed in PBS buffer at pH 7.4 yielded he values of -5.9, -25 
18.3 and -15.6 mV respectively for ORMOSIL, Stober and Ludox 
particles (50 nm diameter). Hence, surface charge is not 
proportional to the amount of acidic Si-OH groups present on the 
particles (corresponding to partially condensed silicon atoms), 
which is greater in Stober particles and smaller in ORMOSIL and 30 
Ludox. Van Blaaderen calculations reveal that surface silanols  
 
Figure 3.Comassie Blue stained SDS-PAGE analysis of nanoparticle-
bound human plasma proteins. 
account for a very small fraction (2,5% for 50 nm diameter 35 
nanoparticles) of the total silicon atoms.23 Hence, even in the 
most condensed particles the amount of silanols detected by 29Si 
MAS NMR groups largely exceed that necessary for a full 
surface coverage. This explains why Stober and Ludox particles 
have similar Z-potential values notwithstanding the large 40 
difference in number of silanols. Once all the available sites on 
the surface are occupied, silanols in excess must locate in the 
nanoparticles interior not affecting the overall surface charge. 
Hence, in the case of ORMOSIL particles, the less-negative Z-
potential could be explained by postulating that several vinyl 45 
moieties are exposed on surface instead of OH groups, and this 
reduces the overall surface charge. The consequences of such a 
relevant difference in the surface chemical structure should be 
observed not only on the Z-potential values but also on the 
interaction with serum proteins, which is fundamental in 50 
determining the biological fate of the nanoparticles.24 To test this 
hypothesis the patterns of protein adsorbed on ORMOSIL and 
Ludox particles, after 3 hours incubation at 37°C in human 
plasma, were identified by SDS-PAGE and mass spectroscopy 
(figure 3). Interestingly, both ORMOSIL and Ludox particles 55 
recruit few and quite different plasma proteins, with Ludox 
interacting preferentially with Immunoglobuline-G (IgG), 
Histidine Rich Glycoprotein (HRG), Human Serum Albumin 
(HSA) and apolipoproteins ApoA-I, ApoA-II, and ApoC-III, 
while ORMOSIL exhibit higher affinity for ApoA-IV, ApoE, 60 
ApoJ and ApoA-I. Hence, the reduction of the surface charge 
(which still remains negative) and the exposure of vinyl residues 
results in a shift of preference from soluble IgG, HSA and HRG 
proteins to more hydrophobic lipoproteins. We previously 
observed that hydrophobic photosensitizers entrapped in the 65 
ORMOSIL where rapidly released from the nanoparticles when 
incubated with serum.17b The high preference for recruiting 
lipoproteins, which are known carriers of hydrophobic species, 
could account for this observation. 
As we have shown earlier, addition of an amphiphilic 70 
trialkoxysilane PEG derivative to the reaction mixture, as 1 in 
Chart 1, results in the formation of densely PEGylated 
nanoparticles.18 PEGylation produces only minor modifications 
on the IR spectrum (Figure 1, green) where a broadening of the  
* *
* *
a
b
T3
T2
T3
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C=C
C-O
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δ, ppm
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Chart 1. Alkoxysilane derivatives used in this work
signals in the 1000-1200 cm-1 range, due to the superimposition 
of the PEG signals, is the main difference observed. PEG features 
are also visible in the 13C MAS solid state NMR signal at 71 ppm, 5 
arising from the methylenes of the polyethylene oxide chain 
(Figure 2b, green). Analysis of this spectrum also reveals the 
absence of residual surfactant in these samples, in contrast with 
the non-PEGylated ORMOSIL nanoparticles (Figure 2b, blue). 
This suggests that the presence of the amphiphilic silane prevents 10 
the surfactant from remaining physically entrapped in the 
ORMOSIL matrix, hence favouring its removal. TGA analysis 
(ESI) reveals that the dense coat of PEG-2000 accounts 
respectively for 67, 38 and 25% of NPs weight for nanoparticles 
with 20, 55 and 70 nm diameters. Such figures lead to estimate a 15 
surface density of 1-2 PEG molecules per nm2.  
Finally, 29Si-NMR indicates a smaller degree of condensation of 
the silicon atoms, with the amount of partially condensed T2 
atoms raised here to 34%. However, both the surface coating with 
PEG and again the presence of a larger amount of silanol groups 20 
in the ORMOSIL matrix appear not to affect the overall surface 
charge, the Z-potential (in PBS buffer, pH 7.4) being −4.3 mV, 
only slightly different form that of the “naked” ORMOSIL 
particles.  
 25 
Photochemical properties of embedded photosensitizers 
Having such a strong influence on the surface properties of the 
nanoparticles, the presence of the vinyl groups is expected to 
affect also the interior silica matrix and as a consequence the 
properties of embedded dyes. This aspect is particularly relevant 30 
for one of the most promising application of VTES-ORMOSIL 
nanoparticles, namely the anticancer modality called 
photodynamic therapy (PDT).9-17 In this approach, a 
photosensitizing molecule should be selectively delivered inside 
the tumour and produce, upon activation with light, cytotoxic 35 
reactive oxygen species (ROS) that kill the tumour cells. 
Remarkably, the photosensitizer does not need to be released 
from the carrier to exert its phototoxic effect and therefore it can 
be embedded in the nanoparticles without the need of devising 
effective release mechanisms. However, the essential requirement 40 
is that the embedded photosensitizer maintains its photophysical 
properties and hence its ability to generate ROS, in particular 
singlet oxygen.  
To investigate this point, we initially prepared both Stöber silica 
nanoparticles and VTES-ORMOSIL nanoparticles (both 45 
PEGylated and not) doped with the alkoxysilane porphyrin 
derivative 3 (we selected this molecule because most of the 
photosensitizers used in clinic are porphyrins or chlorins) and 
investigated the photophysical properties of the embedded dye. 
Inspection of the fluorescence lifetime data reported in Table 1 50 
reveals that all the nanoparticles-embedded dyes (Entries 2-4) 
show biexponential decays with a long component (~10 ns) that 
is very similar to the life-time of 3 in ethanol (Entry 1) and a 
short component (~3 ns) which presumably arises from poorly 
emissive porphyrin aggregates. However, while the short 55 
component is minor in the ORMOSIL particles, it is predominant 
in the Stöber particles (Entry 2), where this behaviour is 
accompanied by a broadening of the porphyrin Soret band in the 
UV-Vis spectrum (ESI). This suggests that the more polar 
environment provided by silica matrix with respect to that of  60 
ORMOSIL favours the formation of weakly fluorescent dye 
aggregates inside the particles, which are known to be ineffective 
as photosensitizers.25 Fluorescence self-quenching through 
interaction of adjacent photosensitiser moieties results in lower  
Si
CH3O
CH3O
CH3O
S
O
O
NH O O O
n
1, n = 44
Si
CH3O
CH3O
CH3O
S
O
O
NH O O NH2
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Table 1. Photophysical properties (fluorescence lifetimes (τ) and their 
amplitudes (A), and singlet oxygen quantum yields (φ∆) of 
photosensitizers embedded in silica (Stöber) and ORMOSIL (OS) 
nanoparticles.a,b 
Entry Dye Np Solvent τ1/ns (A1) τ2/ns (A2) φ∆
e 
1 3 - EtOH 9.5 (100)  - 
2 3 Stoberc H2O 9.6 (55) 2.3 (45) - 
3 3 OSc H2O 11.2 (91) 3.0 (9) - 
4 3 OS/PEGc H2O 12.1 (85) 4.7 (15)
 - 
5 mTHPC - MeOH 8.4 (100) - 0.71 
6 4 - MeOH 8.4 (100) - 0.67 
7 4 OS/PEGd MeOH 8.5 (91) 0.8 (9) - 
8 4 OS/PEG MeOH 8.6 (94) 1.0 (6) 0.55 
9 4 OS/PEG MeOH/H2O 9.7 (90) 1.7 (10) - 
10 4 OS/PEG H2O
 9.9 (83) 0.8 (17) 0.53 
11 5 - MeOH 8.3 (100) - 0.65 
12 5 OS/PEGd MeOH 8.7 (78) 3.4 (22) 0.55 
13 5 OS/PEG MeOH 8.4 (88) 1.2 (12) 0.58 
14 5 OS/PEG MeOH/H2O
 9.9 (52) 0.8 (48) - 
15 5 OS/PEG H2O
 10.0 (18) 0.7 (82) 0.10 
a Nanoparticles diameter 20 nm and average photosensitizer loading 1.5% 5 
w/w unless otherwise stated. bErrors within 5%. c0.3% w/w 
photosensitizer loading. d 90 nm diameter. e φ∆ measured in MeOD except 
Entries 10 and 15, which were carried out in D2O 
triplet state and singlet oxygen yields, and this interaction should 
therefore be minimised as far as possible. The less polar 10 
environment provided by the ORMOSIL matrix hence appears to 
be ideal for accommodating photosensitizer molecules with 
retention of their optimal photophysical properties. 
More insight on this respect was obtained by studying the 
photochemistry of ORMOSIL nanoparticles containing the 15 
alkoxysilane derivatives 4 and 5 of the commercial 
photosensitizer mTHPC (Chart 1). Likewise in the previous case 
fluorescence decay profiles are biexponential, with the long 
component (~8-9 ns) similar to that of the free dye in methanol 
and a short component (~0.5-1 ns). mTHPC in MeOD 20 
(“monomeric mTHPC”) exhibited a φ∆ of 0.71, which is in 
agreement with the literature.26 
In methanol, either mono- and tetra-functionalization of the 
parent mTHPC does not significantly alter the photophysical 
properties of the derivatives (Entries 5, 6 and 11). The singlet 25 
oxygen yields measured for mTHPC in MeOD are in good 
agreement with other studies.26 Also embedding in the 
ORMOSIL matrix does not alter the photosensitizer properties 
(Entries 7-8, 12-13). In fact, in all these cases very similar 
emission lifetimes are observed with a major long-lived 30 
component and a minor short component. However, the situation 
drastically changes when moving to solvents with higher polarity 
(1:1 methanol/H2O, H2O). In the particles doped with 4 the long 
component remains predominant with only a slight increase of 
the short-lived one in more polar solvents (Entries 8-10). 35 
However, in the particles doped with 5, the amplitude of the short 
component is substantially increased in water so that it becomes 
the dominant decay component. The fluorescence emission 
intensity is also substantially quenched compared to methanol 
(Entries 13-15). The behaviour of the emission quantum yield 40 
parallels that of the singlet oxygen quantum yield (measured by 
singlet oxygen phosphorescence at 1270 nm). Singlet oxygen 
production of nanoparticles doped by both the dye in methanol 
and by dye 4 in deuterated water are very similar to that of 
mTHPC in deuterated methanol, on the other hand, singlet 45 
oxygen production by 5-doped nanoparticles in deuterated water 
is much lower (Entry 15). 
The peculiar behaviour of the embedded dye 5 is not due to 
aggregation since it is not loading-dependent (not shown). In this 
case we propose that the penetration of water and resulting H-50 
bonding inside the nanoparticle may lead to distortion of the 
tetra-coordinated chlorin macrocycle since it is rigidly attached to 
the silica matrix and cannot compensate by conformational 
realignment, unlike the mono-coordinated chlorin which is able 
to rotate. Distortion in the macrocycle planarity is well known to 55 
increase the rate of internal conversion resulting in quenching of 
its emission and singlet oxygen production.27 
 
Targeting of the ORMOSIL nanoparticles 
As we earlier demonstrated, functional groups for conjugation of 60 
the nanoparticles to targeting species can be introduced in the 
coating layer by simply adding a second PEG-trialcoxysilane 
derivative bearing a reactive terminal group (Scheme 1).18 To 
further explore such possibility we prepared several batches of 4-
doped ORMOSIL nanoparticles targeted with different bioactive 65 
molecules, such as folic acid, biotin, the cyclic (RGD) peptide 
and the antibody Cetuximab (Chart 2). The nanoparticles were 
prepared in different sizes (20-100 nm) by adding to the reaction 
mixture different amounts of PEG derivatives 1 and 2 (1-30%). In 
the case of folic acid and biotin, which can be directly linked to 70 
the nanoparticles amino groups via the formation of an amide 
bond, targeting was performed by directly adding O-
hydroxysuccinimmide ester derivatives of the targeting agents to 
the reaction mixture before the purification (Scheme 1). In this 
way, dye-doped, PEGylated and targeted nanoparticles could be 75 
prepared by a simple one-pot procedure. The grafting of folate 
and biotin to the nanoparticles was demonstrated by the presence 
of the characteristic spectral features of this molecule in the UV-
Vis spectrum in the case of the first, and by the HABA-Avidin 
and the EZview Red Streptavidin Affinity Gel tests for the second 80 
(see ESI). 
On the contrary, the cyclic(RGD) peptide, which targets the αvβ3  
integrin associated to tumor neovasculature (Chart 2), and the 
Cetuximab antibody, recognizing the Epithelial Growth Factor 
receptor (EGFR) overexpressed in many tumours, were 85 
conveniently conjugated to the nanoparticles by taking advantage 
of thiols group inserted in the derivatives (i.e. in the case of 
Cetuximab thiols group were introduced by reaction with 2-
iminothiolane). This required the conversion of the terminal 
amine groups of the nanoparticles into thiol-reactive maleimide 90 
groups via the reaction with the commercial MBS crosslinker 
(Chart 2). Subsequent reactions with the cyclic(RGD), the 
inactive analogue cyclic(RAD) and iminothiolane modified 
Cetuximab antibody provided the targeted nanoparticles. In this 
case, due to the sensitivity of the maleimide group to 95 
nucleophiles, and to prevent unwanted conjugation between the 
targeting peptide and unreacted MBS, we preferred to perform 
the conjugation with a three step procedure involving  
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Chart 2. Targeting agents used and scheme for the post-synthetic functionalization of 1/2-coated nanoparticles with the peptides and antibodies (TAG). 
nanoparticles purification after each step (Chart 2). Antibody 
conjugation was confirmed by Western Blot analysis (see ESI). 5 
 
Cellular uptake and targeting 
In order to investigate the ability of the PEGylated ORMOSIL 
nanoparticles to enter cancer and healthy cells, free mTHPC and 
4-doped nanoparticles (90 nm diameter) were incubated, at the 10 
same dye concentration, with human lung carcinoma cells A549 
and normal lung fibroblasts CCD-34Lu for 24 h at 37 °C in 
culture medium supplemented with 3% fetal calf serum (FCS). 
The dye uptake was measured by flow cytometry (FACS) 
experiments using the fluorescence emission of the chlorins 15 
associated to the cells. As expected, the cellular uptake of the 
drug by both the cancer (Figure 4) and healthy cells (ESI, Figure 
S10) is greatly reduced by the embedding in the PEGylated 
nanoparticles, with the uptake of the photosensitizer being only 
about 5% of that measured when the free dye is incubated with 20 
the cells. 
These results are important because they clearly indicate that the 
use of the PEGylated nanoparticles as a carrier for the  
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Figure 4. Flow cytometry measurements of mTHPC and derivative 4 25 
uptake in A549 cells incubated for 24 h with increasing concentration of 
free mTHPC (white) or 4-doped PEG-ORMOSIL nanoparticles (grey). 
photosensitizer should minimize unwanted uptake by healthy 
tissues and by consequence reduce the unwanted systemic 
toxicity of the therapy. On the other hand, this ability to escape 30 
cell capture makes conjugation with targeting agents necessary in 
order to trigger active uptake mechanisms and ensure that the 
photosensitizer is delivered to the target cells. We hence 
investigated the “in vitro” uptake of folate-, RGD- and 
Cetuximab-conjugated nanoparticles using cell lines over-35 
expressing the targets recognized by each vehicle moieties. The 
results obtained are quite different with the three guided-
nanosystems.  
In the case of folate, KB cells overexpressing and A549 cells not 
expressing the folate receptor were used. The presence of the 40 
folate in the nanoparticles coating results in (see ESI): i) 
decreased uptake with respect to nanoparticles coated with only 
PEG; ii) no difference in the uptake of folate-nanoparticles 
between KB and A549 cells (not shown) and; iii) no inhibition of 
the uptake of folate-targeted nanoparticles in KB cells 45 
preincubated with 1 mM free folic acid to saturate the receptor 
and prevent the internalization of the nanoparticles through the 
receptor-driven specific endocytosis. Such behavior is not 
affected by the size of the nanoparticles or by the thickness of the 
PEG coating or the length of the PEG functioning as a linker for 50 
folate. 
Different results were obtained with the RGD-targeted 
nanoparticles incubated with HUVEC cells overexpressing the 
integrin αvβ3 receptors for RGD. We evaluated the efficiency of 
the targeting agent on the same cell line by comparing the uptake 55 
of the RGD-targeted nanoparticles with that of identical particles 
(prepared from the same original batch) targeted with the RAD 
peptide, where the substitution of the central glycine with an 
alanine prevents the recognition by the integrins. Inspection of 
the results reported in Figure 5 provides evidence of higher 60 
uptake of the RGD-conjugated nanoparticles with respect to the 
RAD-conjugated ones. The uptake improves by increasing the 
amount of RGD peptides present in the nanoparticles coating 
layer form 15 to 30%, while uptake slightly decreases using 
smaller nanoparticles (40 nm diameter). The different behaviour  65 
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Figure 5. Flow cytometry measurements of mTHPC derivative 4 uptake 
in HUVEC cells incubated for 3 or 24 h with 4-doped PEG-ORMOSIL 
nanoparticles of different size and conjugated with RGD and RAD 
peptides in different amounts. 5 
between the two small-molecule targeting agents is not 
unprecedented in PLGA nanoparticles and was attributed to poor 
surface exposure of the hydrophobic folate moiety.28 Moreover, it 
has been recently reported that a dense PEG layer coating silica 
nanoparticles can effectively capture and incorporate organic 10 
dyes from water solution.29 It can hence be expected that the long 
PEG3300 linker, bearing the targeting agent, folds allowing to the 
folate moiety to hide in the PEG layer. In support of this view, 
some of us recently found that only liposomes with a degree of 
PEGylation not higher than 8% the folate conjugation slightly 15 
improved the selectivity of mTHPC uptake in KB cells.30 
Furthermore, the decreasing uptake of folate ORMOSIL 
nanoparticles with the increasing of the folate percentage might 
indicate changes of the surface properties that make cell 
internalization less efficient. The zwitterionic RGD peptide is 20 
much more hydrophilic than folate and hence it is likely less 
attracted by the PEG pseudophase, therefore remaining available 
for the interaction with the cellular receptor.  
Such a picture is confirmed by the results obtained with the 4-
doped nanoparticles conjugated with the antibody Cetuximab  25 
(Figure 6). Here the size of the targeting agent (i.e. the average 
size of an antibody is 15×8×4 nm31) is such that the interference 
of the PEG coating with its binding efficiency appear to be 
unlikely. In fact, internalization of targeted nanoparticles at 37°C, 
measured on the A431 cells overexpressing the EGF receptor, is 30 
impressive. The uptake of the conjugated nanoparticle is at least 
20-fold greater than that of the unconjugated or BSA-conjugates 
(prepared as negative control systems). The specific uptake of 
Cetuximab-guided nanoparticles on A431 cells was confirmed by 
competition experiments performed by co-incubating cells, at 35 
37°C, with increased concentrations of free Cetuximab (Figure 
7). In fact the co-incubation of targeted nanoparticles with free 
Cetuximab reduces the nanoparticle uptake of about 93%, 
whereas no decrease of nanosystem uptake is observed for BSA-
conjugated control particles in the same conditions (see ESI). 40 
Further assays were performed to obtain more insight on the 
internalization mechanism. First the dependence of the uptake by 
the amounts of Cetuximab or BSA-conjugated nanoparticles  
 
Figure 6. Differential uptake of 4-doped PEG-ORMOSIL nanoparticles 45 
unconjugated (NPs alone), or conjugated with Cetuximab and BSA on 
A431 cells. Cells were incubated with nanoparticles at 1 µM 
concentration of  dye 4 for 90 minutes at 37°C, nanoparticle uptake was 
analyzed by flow cytometry.      
added was investigated (see ESI) and demonstrated that the 50 
internalization mechanism of the antibody-guided nanovectors is 
saturable. In fact, the amount of taken-up nanoparticles does not 
increases linearly with the amount of nanoparticles added and 
appears to reach a plateau for nanoparticles concentrations of 320 
µg/mL (corresponding to a dye concentration of 4 µM). Such  55 
behavior suggests that, once all the EGF receptors available on 
the surface of the cells are bound to antibodies conjugated with 
the nanoparticles, further increments of the nanoparticles 
concentrations do not result in increased uptake, as expected for a 
receptor mediated internalization mechanism. Indeed the BSA-60 
conjugated nanoparticle uptake appears to follow a different trend 
with a linear concentration-dependent increase of the uptake in 
the interval studied.  
The same picture emerged from time-dependant analysis 
performed using in this case three different cell lines (see ESI):  65 
 
Figure 7. Displacement of the uptake of 4-doped PEG-ORMOSIL 
nanoparticle conjugate with Cetuximab on A431 cells by free Cetuximab. 
Cells were incubated with nanoparticles at 0.25 µM concentration of  dye  
4 and increasing concentrations of free Cetuximab for 90 minutes at 70 
37°C, nanoparticles uptake was analysed by FACS.  
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Figure 8. Nanoparticles induced down-regulation (measured as amount of 
cell bound FITC-labelled anti EGFR antibody) of EGF receptor in 
different cell lines. Cells were incubated in DMEM 10 % FCS with 
different concentrations of Cetuximab () or  BSA () conjugated 5 
nanoparticles for  two hours at 37°C; washed and  analysed by FACS. 
Note the different signal intensities in the three cell lines, proportional to 
plasma membrane EGFR amounts. 
normal HeLa cells, expressing basal amounts of plasma 
membrane located EGFR, a derived HeLa cell lines, permanently 10 
transfected to express higher levels of surface EGFR (4-5 folds 
the parental HeLa cell line) and the above mentioned A431 cells,  
expressing a high amount of EGFR (10-13 folds in the plasma 
membrane compared to HeLa cells). As expected, Cetuximab-
conjugated nanoparticles uptake is not linear with incubation time 15 
and reaches a saturation level after about 2 hours with all the cell 
lines. Moreover, the amount of nanoparticles taken up at 
saturation is directly correlated with the extent of EGFR 
expression levels, with A431 and transfected HeLa internalizing 
upon prolonged incubation an amount of nanoparticles about 20- 20 
and 4-fold larger than normal HeLa. On the other hand, non-
specific uptake of BSA-conjugated nanoparticles appears to 
occurs with a slower and cell line-independent kinetic that does 
not reach saturation values in the time span explored. As a 
consequence, maximum preferential uptake is observed for short 25 
 
Figure 9. Colocalization of Cetuximab and dye 4 upon incubation of 
EGFR positive A431 cells, EGFR over-expressing HeLa and parental 
HeLa (having reduced EGFR levels) with Cetuximab conjugated 4-doped 
ORMOSIL nanoparticle at 1 µM mTHPC concentration for two hours at 30 
37°C. Green signal is Cetuximab distribution, red one is mTHPC. Arrows 
point the colocalisation of Cetuximab and mTHPC. 
incubation times. 
The specific interaction of the nanoparticles with EGFR, 
followed by internalisation of the resulting complex, was clearly 35 
documented by further experiments in which the amount of  
surface receptors was quantified by FACS after incubation with 
nanoparticles using a fluorescein-conjugated Cetuximab as a 
label (Figure 8). Indeed, Cetuximab-conjugated nanoparticles, but 
not BSA-conjugated ones, down regulate EGFRs in all cell types, 40 
suggesting, in agreement with confocal microscopy (see infra), 
that complexes between Cetuximab-nanoparticles and EGFRs, 
formed on the plasma membrane, are internalised in endosomes 
and this leads to a decrease of the amount of receptor on the cell 
surface. EGFR down regulation is complete at very low 45 
nanoparticles concentrations (50 µg/mL for A431 cells, 
corresponding to a 4 concentration of 0.62 µM). Confocal 
microscopy analysis experiments (Figure 9) enabled   localisation 
of both nanoparticle-linked Cetuximab (by staining with a 
fluorescein labelled anti-human antibody) and of the 50 
nanoparticle-linked dye 4. The experiment confirmed that the 
nanoparticles bind more effectively to cells overexpressing the 
EGFR, with localized emission of dye 4 suggesting endosomial 
localization, while the high degree of colocalization of 
Cetuximab and 4 indicates that the nanoparticles maintain their 55 
integrity upon internalization. 
Taken together, all these experiments confirm an active uptake 
mechanism, where the targeted nanoparticles bind to the EGF 
receptors available on the cell surface and are internalized by 
endocytosis. On the other hand, untargeted nanoparticles are 60 
taken up by a slow and non saturable passive mechanism. Hence, 
optimal selectivity can be achieved for relatively low doses and 
incubation times. 
Finally from the  perspective of future “in vivo” evaluations, we 
investigated the serum stability of our protein conjugated-65 
nanosystems. The nanoparticles functionality, assessed as binding 
and uptake capabilities on A431 cells, decreases of less than 20% 
when the incubation of Cetuximab-conjugated nanoparticles was 
performed in 100% of serum (i.e. 90 minutes at 37°C). The good 
serum stability was also confirmed when longer incubation times 70 
were applied (i.e. 32% of functionality was preserved after 16hrs 
of serum pre-treatment, data not shown). 
 
PDT experiments 
The phototoxicity of 4 delivered by nanoparticles was determined 75 
both in the case of RGD- and Cetuximab-conjugated 
nanoparticles. In the case of RGD nanoparticles, a significant 
reduction of the cell viability was found after irradiation of the 
cells incubated with the 4-loaded nanoparticles, demonstrating 
the photokilling activity of the dye embedded in the 80 
nanoparticles. Disappointingly, the dose-response curve obtained 
by treatment of the HUVEC cells with RGD-conjugated 
nanoparticles was in any case perfectly superimposed (see SI) to 
that of RAD-conjugated nanoparticles. A possible explanation of 
such a behaviour is based on the findings of Allen and co-85 
workers that suggest that RGD, but not RAD, partially protect the 
cells from PDT induced death by exerting an anti-oxidant and/or 
anti-apoptotic effect.32 
Better results were obtained with the Cetuximab-conjugated 
nanoparticles (Figure 10), but only when prolonged (6 hours)  90 
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Figure 10. Photokilling efficiency of Cetuximab- and BSA-conjugated 4-
loaded PEG-ORMOSIL nanoparticles upon incubation for 6 hours with 
different cell lines and light exposure. A) Amount of cell killed with 
respect to the control at increasing nanoparticle doses. B) Ratio of 5 
photokilling activity between targeted and control nanoparticle on the 
different cell lines as a function of the dose administered.  
incubation times where applied. As revealed from figure 10A, 
absolute photokilling efficiency does not correlate with uptake in 
the different cell lines, likely as a result of a different ability of 10 
the cell line to resist to cytotoxicity of generated ROS. However, 
when the attention is focused on the difference between the 
activity of the targeted and untargeted nanoparticles with each 
cell line, it appears evident as the Cetuximab-conjugated 
nanoparticles are substantially more efficient in photokilling 15 
A431 cells (up to 8-fold) than the BSA-conjugated counterparts 
when delivered at doses well below the EGF receptors saturation 
level. This difference rapidly decreases when the nanoparticles 
dose is increased, possibly because the non-specific uptake of the 
untargeted particles becomes more relevant with respect to the 20 
receptor-mediated uptake at this prolonged incubation times, or 
when cells express a lower (HeLa-EGFR, 40% of EGFR with 
respect to A431) or negligible (HeLa) amount of EGF receptor. 
Shorter incubation times at low doses led to negligible 
photokilling. As a matter of fact,  when compared with free 25 
mTHPC delivered as standard formulation, Cetuximab- 
conjugated nanoparticles are still less efficient in producing 
photoxicity. The photochemical investigations reported in the 
previous paragraph exclude the possibility that such a result 
arises from a lower efficiency of singlet oxygen production by the  30 
nanoparticle-embedded photosensitizer. On the other hand, 
unfavourable localization of the nanoparticles inside the cells 
could result into a lower cytotoxic activity of the singlet oxygen 
produced. In fact, it is well-known that mTHPC mainly localises 
in the Golgi apparatus and the endoplasmic reticulum, while we 35 
have showed here that 4-loaded Cetuximab-conjugated 
nanoparticles are found essentially in endosomal vesicles. 
Conclusions 
In summary, the results reported provide interesting insight on 
how to optimise the properties of VTES-ORMOSIL nanoparticles 40 
for biomedical applications, and in particular for targeted therapy. 
Being designed to operate in a very complex environment such as 
a living organism, such nanoparticles require a precise design 
which in turn needs detailed chemical and structural 
characterization. The first feature that  emerges is the flexibility 45 
of the synthetic procedure, which enables the one-pot preparation 
of nanoparticles loaded with the active agent, PEGylated and 
either targeted or ready for post-targeting. However, realization 
of such a multifunctional entity requires taking into account all 
the possible interactions between the components. The 50 
organosilica matrix provides a low polarity environment that 
preserves the photochemical properties of the embedded 
photosensitizer while maintaining water accessibility, but 
excessive rigidity of the framework, as here in the case of 
tetrasilane derivative 5, may result in an unanticipated 55 
perturbation to the photophysical properties in aqueous solution 
leading to a reduced singlet oxygen yield. Dense PEGylation 
minimizes toxicity and RES capture, but also uptake by cells. 
This enables higher selectivity with active targeting strategies, as 
we demonstrated using the Cetuximab targeting agent. On the 60 
other hand, the possibility of adverse interactions between the 
targeting molecules and the stealth-conferring layer to which they 
are grafted, as here in the case of folate, must be taken in to 
account and prevented. 
Another important feature is the interaction with proteins, which 65 
is fundamental in determining the final fate of a nanoparticle 
following administration. The results reported herein suggest that 
not only we can prevent such interactions, as is well known, by 
coating the particles with PEG or other hydrophilic molecules, 
but also we can select the interacting proteins by finely tuning the 70 
surfaces properties, as here shown in the case of VTES and 
Stöber particles. 
Finally, we explored the  crucial point of selective targeting and  
the importance of the subcellular fate of the nanoparticles. The 
results we report on RGD and Cetuximab-conjugated 75 
nanoparticles clearly show that increased uptake arising from 
efficient targeting is not sufficient to ensure  higher therapeutic 
efficiency. In particular data obtained with Cetuximab were very 
informative, since they clearly indicate that differential binding to 
tumor model cells of nanoparticles and hence of mTHPC loading 80 
may be achieved only at doses of ligand-linked nanoparticles that 
do not saturate the internalization mechanism. Once these 
specific sites are saturated, non-specific and non-saturable 
binding sites become more  relevant upon increasing the applied 
nanoparticle concentrations. The resulting paradox is that 85 
selective photokilling was only achieved under conditions of 
partial killing efficacy. Moreover, subcellular localization may 
also play an important role in explaining the correlation between 
uptake and PDT efficacy, since the amount of photosensitizer 
internalized could not be a good parameter to evaluate the real 90 
amount of effective photosensitizer, i.e. the fraction localized at 
critical sites more susceptible to generated ROS.  
These observations may lead to the development of new 
strategies to improve the intrinsic efficacy of the nanoparticles-
carried photosensitizer inside the cell, a parameter that, in the 95 
end, appears to be the most critical and limiting to gain effective 
neoplastic cell disruption. The implementation of active release 
mechanisms or the addition of other chemical determinants to the 
nanoparticle coating layer capable of re-directing them to more 
sensitive intracellular sites/organelles, or helping their 100 
translocation to the cell cytoplasm, could provide solutions to this 
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problem. All this information provides a useful framework in the 
development of new nanosystems for tumor therapy. 
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Highly flexible ORMOSIL nanoparticles can be PEGylated, doped with photoactive species, 
targeted for selective recognition of cancer cells. 
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